Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Shionogi
Pharma
Eisai, Takeda, BIOSECURE Act—Fierce Pharma Asia
Eisai projected a sales increase for Leqembi. Takeda gained an option to license an Alzheimer's therapy. A House committee advanced the BIOSEUCRE Act.
Angus Liu
May 17, 2024 8:30am
Shionogi's antiviral comes up short in global COVID-19 trial
May 13, 2024 10:48am
Orchid granted license to produce antibiotic to meet global need
Sep 12, 2023 9:55am
Shionogi, Takeda, AbbVie-BeiGene—Fierce Pharma Asia
Jun 30, 2023 9:45am
Daiichi Sankyo is setting up Japan's first mRNA plant
Feb 7, 2023 10:43am
Eisai, BeiGene, Shionogi—Fierce Pharma Asia
Dec 2, 2022 10:00am
